View text source at Wikipedia

Saxagliptin

Saxagliptin
Clinical data
Trade namesOnglyza
Other namesBMS-477118
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa610003
License data
Pregnancy
category
  • AU: B3
Routes of
administration		By mouth (tablets)
Drug classDPP-4 inhibitors
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
Pharmacokinetic data
Bioavailability~75% (Tmax = 2 h)
Protein bindingnegligible
MetabolismLiver (CYP3A4 and CYP3A5)
Elimination half-life2.5 h (saxagliptin), 3.1 h (main metabolite)
Excretion22% (Bile duct), 75% (Urine)
Identifiers
  • (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H25N3O2
Molar mass315.417 g·mol−1
3D model (JSmol)
  • O=C(N1[C@H](C#N)C[C@@H]2C[C@H]12)[C@@H](N)C35CC4CC(C3)CC(O)(C4)C5
  • InChI=1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15-,17?,18?/m1/s1 checkY
  • Key:QGJUIPDUBHWZPV-SGTAVMJGSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Saxagliptin, sold under the brand name Onglyza, is an oral hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class.[1][2] Early development was solely by Bristol-Myers Squibb; in 2007 AstraZeneca joined with Bristol-Myers Squibb to co-develop the final compound and collaborate on the marketing of the drug.

In April 2016, the U.S. FDA added a warning about increased risk of heart failure.[3] This was based on data in an article that concluded "DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes."[4]

Medical uses

[edit]

Saxagliptin is used as monotherapy or in combination with other drugs for the treatment of type 2 diabetes. It does not appear to decrease the risk of heart attacks or strokes.[4] One study showed a 3.5% risk of hospitalization for heart failure compared to 2.8% in a placebo-controlled group. Like other DPP-4 inhibitors, it has relatively modest HbA1c lowering ability, is associated with a relatively low risk of hypoglycemia, and does not cause weight gain.[4][5]

Saxagliptin improved mean HbA1c levels (relative to placebo) in a 24-week trial in people with type 2 diabetes.[6] Combination therapy with saxagliptin and metformin was more effective than saxagliptin or metformin monotherapy.[6] When the relative benefits of increasing the dose of a sulfonylurea or adding saxagliptin were assessed in a study of 768 patients, combination treatments were shown to have a significantly greater impact on fasting blood glucose than increasing the tested glibenclamide dose alone.[7]

Adverse effects

[edit]

In those taking sulphonylureas there is an increased risk of low blood sugar.[8]

3 adverse reactions were seen higher in saxagliptin vs placebo. Table 1: Adverse Reactions (Regardless of Investigator Assessment of Causality) in Placebo-Controlled Trials* Reported in ≥ 5% of Patients Treated with ONGLYZA (saxagliptin tablets) 5 mg and More Commonly than in Patients Treated with Placebo.[9]

Number (%) of Patients
ONGLYZA 5 mg N=882 Placebo N=799
Upper respiratory tract infection 68 (7.7) 61 (7.6)
Urinary tract infection 60 (6.8) 49 (6.1)
Headache 57 (6.5) 47 (5.9)[9]

In February 2012, Bristol-Myers/Astra Zeneca distributed additional safety information on saxagliptin use in South Africa. The package insert is to be edited for South Africa. Contraindications will now include a history of sensitivity to saxagliptin (or another DPP4 inhibitor) as well as pancreatitis. Spontaneously reported adverse events in South Africa have included anaphylaxis, angioedema and acute pancreatitis.[medical citation needed]

In a cardiovascular outcomes trial, saxagliptin treatment let to a small increase in the risk of being hospitalized for heart failure.[4] Saxagliptin may cause joint pain that can be severe and disabling.[10] Saxagliptin may increase the risk of heart failure.[11]

Tolerability

[edit]

Both monotherapy and combination therapy with other agents was generally well tolerated in clinical trials.[6]

Pancreatitis and pancreatic cancer

[edit]

An association of the DPP-IV inhibitor class with pancreatic problems has been proposed, mainly based on case reports associated with the DPP-IV inhibitor sitagliptin and several incretin mimetics including exenatide. A 2013 study of the DPP-4 inhibitor sitagliptin reported found "worrisome changes in the pancreases of the rats that could lead to pancreatic cancer".[12] A second paper by the same authors reported an increase in precancerous lesions in the pancreases of organ donors who had taken GLP-1 inhibitors.[13] In response to these reports, the United States FDA and the European Medicines Agency each undertook independent reviews of all clinical and preclinical data related to the possible association of DPP-IV inhibitors with pancreatic cancer. In a joint letter to the New England Journal of Medicines, the agencies stated that "Both agencies agree that assertions concerning a causal association between incretin-based drugs and pancreatitis or pancreatic cancer, as expressed recently in the scientific literature and in the media, are inconsistent with the current data. The FDA and the EMA have not reached a final conclusion at this time regarding such a causal relationship. Although the totality of the data that have been reviewed provides reassurance, pancreatitis will continue to be considered a risk associated with these drugs until more data are available; both agencies continue to investigate this safety signal."[14]

Lawsuits have been filed in which plaintiffs who developed pancreatic cancer claim that DPP-IV inhibitors or incretins had a causative role in the development of their cancers.[15]

Production

[edit]

The synthesis of saxagliptin by Bristol-Myers Squibb by the amide coupling of N-Boc-3-hydroxyadamantylglycine (2) and methanoprolineamide (3) with EDC. The former is commercially available, whereas the latter is available as the N-Boc analog. The prolineamide moiety is subsequently dehydrated with trifluoroacetic anhydride to give the cyanide as the trifluoracetate ester, which is hydrolyzed. Removal of the Boc protecting group, followed by neutralization gives the desired product (1):[16]

Pharmacology

[edit]

Saxagliptin is part of a class of diabetes medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. DPP-4 is an enzyme that breaks down incretin hormones. As a DPP-4 inhibitor, saxagliptin slows down the breakdown of incretin hormones, increasing the level of these hormones in the body. It is this increase in incretin hormones that is responsible for the beneficial actions of saxagliptin, including increasing insulin production in response to meals and decreasing the rate of gluconeogenesis in the liver.[17]

Dipeptidyl peptidase-4's role in blood glucose regulation is thought to be through degradation of GIP[18] and the degradation of GLP-1.[18][19]

Because incretin hormones are more active in response to higher blood sugar levels (and are less active in response to low blood sugar), the risk of dangerously low blood sugar (hypoglycemia) is low with saxagliptin monotherapy.

Licensing

[edit]

A New Drug Application for saxagliptin in the treatment of type 2 diabetes was submitted to the FDA in June 2008. It was based on a drug development program with 8 randomized trials: 1 phase 2 dose-ranging (2.5–100 mg/d) study; 6 phase 3, 24-week controlled trials with additional controlled follow-up from 12 to 42 months, double-blinded throughout; and one 12-week mechanism-of-action trial with a 2-year follow-up period.[20] The FDA approved saxagliptin with brand name Onglyza on July 31, 2009.[21] Saxagliptin was licensed for use throughout the European Union by the European Medicines Agency on December 1, 2009.[22] Bristol-Myers Squibb announced on 27 December 2006 that Otsuka Pharmaceutical Co. has been granted exclusive rights to develop and commercialize the compound in Japan. Under the licensing agreement, Otsuka will be responsible for all development costs, but Bristol-Myers Squibb retains rights to co-promote saxagliptin with Otsuka in Japan.[23] Further, on 11 January 2007 it was announced that Bristol-Myers Squibb and AstraZeneca would work together to complete development of the drug and in subsequent marketing.[24]

References

[edit]
  1. ^ Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, et al. (July 2005). "Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes". Journal of Medicinal Chemistry. 48 (15): 5025–5037. doi:10.1021/jm050261p. PMID 16033281.
  2. ^ "Bristol, Takeda Drugs Offer Alternatives to Januvia (Update2)". Bloomberg. 2008-06-07.
  3. ^ "Safety Alerts for Human Medical Products - Diabetes Medications Containing Saxagliptin and Alogliptin: Drug Safety Communication - Risk of Heart Failure". www.fda.gov. Retrieved 7 April 2016.
  4. ^ a b c d Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. (October 2013). "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus". The New England Journal of Medicine. 369 (14): 1317–1326. doi:10.1056/nejmoa1307684. hdl:10044/1/40070. PMID 23992601. S2CID 5080046.
  5. ^ Ali S, Fonseca V (January 2013). "Saxagliptin overview: special focus on safety and adverse effects". Expert Opinion on Drug Safety. 12 (1): 103–109. doi:10.1517/14740338.2013.741584. PMID 23137182. S2CID 12634714.
  6. ^ a b c Dhillon S, Weber J (October 2009). "Saxagliptin". Drugs. 69 (15): 2103–2114. doi:10.2165/11201170-000000000-00000. PMID 19791828. S2CID 243454677.
  7. ^ "New Drugs: Saxagliptin". Australian Prescriber (34): 89–91. June 2011. Archived from the original on 2014-02-02. Retrieved 2011-06-17.{{cite journal}}: CS1 maint: unfit URL (link)
  8. ^ Salvo F, Moore N, Arnaud M, Robinson P, Raschi E, De Ponti F, et al. (May 2016). "Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis". BMJ. 353: i2231. doi:10.1136/bmj.i2231. PMC 4854021. PMID 27142267.
  9. ^ a b c "Onglyza". RxList. Retrieved 2012-01-31.
  10. ^ "DPP-4 Inhibitors for Type 2 Diabetes: Drug Safety Communication - May Cause Severe Joint Pain". U.S. Food and Drug Administration (FDA). 2015-08-28. Retrieved 1 September 2015.
  11. ^ "FDA Drug Safety Communication: FDA adds warnings about heart failure risk to labels of type 2 diabetes medicines containing saxagliptin and alogliptin". U.S. Food and Drug Administration (FDA). 12 January 2017. Retrieved 11 August 2020.
  12. ^ Matveyenko AV, Dry S, Cox HI, Moshtaghian A, Gurlo T, Galasso R, et al. (July 2009). "Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin". Diabetes. 58 (7): 1604–1615. doi:10.2337/db09-0058. PMC 2699878. PMID 19403868.
  13. ^ Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC (July 2013). "Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors". Diabetes. 62 (7): 2595–2604. doi:10.2337/db12-1686. PMC 3712065. PMID 23524641.
  14. ^ Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, Rosebraugh C (February 2014). "Pancreatic safety of incretin-based drugs--FDA and EMA assessment". The New England Journal of Medicine. 370 (9): 794–797. doi:10.1056/NEJMp1314078. PMID 24571751.
  15. ^ "IN RE: INCRETIN MIMETICS PRODUCTS LIABILITY LITIGATION" (PDF). USJP. United States Judicial Panel on Multidistric Litigation. August 26, 2013. Retrieved 2013-08-26.
  16. ^ Scott AS, Gregory SJ, Sergei K, Shelly AR, Truc V, Robert EW (2009). "Preparation of Saxagliptin, a Novel DPP-IV Inhibitor". Org. Process Res. Dev. 13 (6): 1169–1176. doi:10.1021/op900226j.
  17. ^ "Onglyza". eMedTV. Clinaero, Inc. Archived from the original on 14 June 2021.
  18. ^ a b Mentlein R, Gallwitz B, Schmidt WE (June 1993). "Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum". European Journal of Biochemistry. 214 (3): 829–835. doi:10.1111/j.1432-1033.1993.tb17986.x. PMID 8100523.
  19. ^ Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A (May 2004). "Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes". The Journal of Clinical Endocrinology and Metabolism. 89 (5): 2078–2084. doi:10.1210/jc.2003-031907. PMID 15126524.
  20. ^ Frederich R, Alexander JH, Fiedorek FT, Donovan M, Berglind N, Harris S, et al. (May 2010). "A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes". Postgraduate Medicine. 122 (3): 16–27. doi:10.3810/pgm.2010.05.2138. PMID 20463410. S2CID 10975424.
  21. ^ Telegram (2 August 2009). "FDA approves diabetes drug from two area manufacturers". Worcester Telegram & Gazette Corp. Archived from the original on 2009-08-07. Retrieved 2009-08-02.
  22. ^ "Assessment report for ONGLYZA" (PDF). European Medicines Agency.
  23. ^ "Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Announce Exclusive Licensing Agreement for Diabetes Compound Saxagliptin in Japan" (Press release). Bristol-Myers Squibb. December 27, 2006. Retrieved 2006-12-27.
  24. ^ "AstraZeneca teams with Bristol-Myers on diabetes drugs". Delaware News-Journal. Associated Press. 11 January 2007. Archived from the original on September 30, 2007. Retrieved 2007-01-11.
[edit]